Basic principles for the management of neurological patients during the COVID-19 pandemic

In a COVID-19 pandemic, a neurologist needs to be able to assess the risks of virus infection in patients with individual neurological diseases. The review presents categories of risk groups from the Association of British Neurologists for neuromuscular diseases, multiple sclerosis and other autoimmune diseases of the central nervous system, stroke, epilepsy and Parkinson’s disease. The risk of infection and the management of patients with neuromuscular diseases are analyzed in detail. The use of multiple sclerosis disease modifying drugs, the treatment of stroke patients are discussed. The data from the international guidelines for the management of patients with epilepsy and Parkinson’s disease are presented.

1. Baklaushev V.P., Kulemzin S.V., Gorchakov A.A. et al. COVID-19. Etiology, pathogenesis, diagnosis and treatment. Klinicheskaya praktika = Clinical practice 2020;11(1):100–13. (In Russ.)

2. Pérez C.A. Looking ahead: The risk of neurologic complications due to COVID-19. Neurol Clin Pract 2020:22. DOI: 10.1212/CPJ.0000000000000836.

3. ABN Executive in association with subspecialist Advisory groups. Association of British Neurologists Guidance on COVID-19 for people with neurological conditions, their doctors and carers. Version 6 (09.04.2020). URL: https://cdn.ymaws.com/www.theabn.org/resource/collection/65C334C7-30FA-45DB-93AA-74B3A3A20293/ABN_Neurology_COVID-19_Guidance_v6_9.4.20_FP.pdf.

4. Dong X., Cao Y.Y., Lu X.X. et al. Eleven faces of coronavirus disease 2019. Allergy 2020:1–11. DOI: 10.1111/all.14289. PMID: 32196678.

5. Interactionchecker. COVID-19 drug interaction. University of Liverpool. URL: https://www.covid19-druginteractions.org.

6. Temporary methodological recommendations of Ministry of health of Russia “Prevention, diagnosis and treatment of the new coronavirus infection (COVID-19). Moscow, 2020. Version 5(08.04.2020)”. URL: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/049/986/original/09042020_%D0%9C%D0%A0_COVID-19_v5.pdf. (In Russ.)

7. Caring for people at highest clinical risk during COVID-19. Background and FAQs for Clinicians (03.04.2020). URL: https://www.qmul.ac.uk/blizard/ceg/media/blizard/images/documents/ceg-documents/Appendix-1--Clinician-FAQs.pdf.

8. Bersano A., Pantoni L. On being a neurologist in Italy at the time of the COVID-19 outbreak. Neurology 2020;Apr 3:pii:10.1212/WNL.0000000000009508. DOI: 10.1212/WNL.0000000000009508. PMID: 32245844.

9. Jacob S., Muppidi S., Guidon A. et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic, Journal of the Neurological Sciences 2019;412:116803. DOI: 10.1016/j.jns.2020.116803. PMID: 32247193.

10. Bolanos-Meade J., Zhou L., Hoke A. et al. Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graft-versus-host disease. Am J Hematol 2005;78:306–9. DOI: 10.1002/ajh.20294. PMID: 15795921.

11. Khosa S., Khanlou N., Khosa G.S., Mishra S.K. Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities. Neuropathology 2018;38:646–2. DOI: 10.1111/neup.12520. PMID: 30411412.

12. Bauman J.L., Tisdale J.E. Chloroquine and hydroxychloroquine in the era of SARS-CoV2: caution on their cardiac toxicity. Pharmacotherapy 2020;Apr 13:published online. DOI: 10.1002/phar.2387. PMID: 32285489.

13. British Inherited Metabolic Disease Group (BIMDG). Inherited metabolic disease and coronavirus (COVID-19) Advice for patients/parents/guardians. (16.03.2020). URL: http://www.bimdg.org.uk/site/news.asp.

14. General advice regarding Coronavirus (COVID-19) for patients with rare genetic disorders. URL: https://www.ouh.nhs.uk/clinical-genetics/documents/coronavirus-2020.pdf.

15. Chest foundation. COVID-19 resources: care recommendations for home-based ventilation patients. (27.03.2020). URL: https://neuromuscularnetwork.ca/files/COVID-19-Resources-Care-Recommendations-for-Home-Based-Ventilation-Patients.pdf.

16. Bojko A.N., Lashch N.Yu., Spirin N.N. et al. Management of patients with Multiple Sclerosis in the context of COVID-19 pandemic. Available at: https://www.ructrims.org/files/2020/%D0%A0%D0%A1_%D0%B8_COVID-19_%D0%A0%D0%B5%D0%BA%D0%BE%D0%BC%D0%B5%D0%BD%D0%B4%D0%B0%D1%86%D0%B8%D0%B8_%D0%92%D0%9E%D0%9D.pdf (in Rus.)

17. ABN Guidance on the use of diseasemodifying therapies in Multiple Sclerosis in response to the threat of a coronavirus epidemic. Version 4(02.04.2020). URL: https://cdn.ymaws.com/www.theabn.org/resource/collection/65C334C7-30FA-45DB-93AA-74B3A3A20293/02.04.20_ABN_Guidance_on_DMTs_for_MS_and_COVID19_VERSION_4_April_2nd.pdf

18. Medical association of doctors and centers of MS and other neuro-immunology diseases (MAVRS). Guideline for treating patients with Multiple Sclerosis during the COVID-19 pandemic (22.03.2020). URL: https://www.centrems.com/downloads/MAVRS-COVID-19.pdf.(in Rus).

19. Novi G., Mikulska M., Briano F. et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord 2020;42:10212. DOI: 10.1016/j.msard.2020.102120. PMID: 32315980.

20. Bornstein S.R., Rubino F., Khunti K. et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes & Endocrinology 2020;Apr 23: published online. DOI: 10.1016/S2213-8587(20)30152-2.

21. Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8(4):e21. DOI: 10.1016/S2213-2600(20)30116-8. PMID: 32171062.

22. Procedure of providing medical assistance for patients with acute impairment of cerebral circulation, approved by the order of Ministry of health of Russian Federation №928н, 15.11.2012 г.(in Rus)

23. AHA/ASA Stroke Council Leadership. Temporary emergency guidance to US stroke centers during the COVID-19 pandemic. Stroke 2020;Apr 15:published online. DOI: 10.1161/STROKEAHA.120.030023. PMID: 32233972.

24. McNamara D. COVID-19 linked to large vessel stroke in young adults. N Engl J Med 2020;Apr 29:published online. URL: https://www.medscape.com/viewarticle/929345

25. Guo T., Fan Y., Chen M. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;Mar 27:published online. DOI: 10.1001/jamacardio.2020.1017.

26. Klok F.A., Kruip M.J.H.A., van der Meer N.J.M. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Resb 2020;Apr 10:published online. DOI: 10.1016/j.thromres.2020.04.013. PMID: 32291094.

27. Baig A.M., Khaleeq A, Ali U. et al. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020:0–3. DOI: 10.1021/acschemneuro.0c00122. PMID: 32167747.

28. Desforges M., Le Coupanec A., Dubeau P. et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses 2019;12(1):14. DOI: 10.3390/v12010014. PMID: 31861926.

29. Li Y.C., Bai W.Z., Hashikawa T. The neuroinvasive potential of SARSCoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients. J Med Virol 2020:24-27. DOI: 10.1002/jmv.25728.

30. Mazya M., Egido J.A., Ford G.A. et al. SITS Investigators. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke 2012;43(6):1524–31. DOI: 10.1161/STROKEAHA.111.644815. PMID: 22442178.

31. Martynov M.Yu., Shamalov N.A., Hasanova D.R. et al. Management of patients with acute stroke in the context of COVID-19 pandemic. Temporary methodological recommendations. Version 1(06.04.2020). URL: http://www.evidence-neurology.ru/content/downloadfiles/1/vedenie-patsientov-s-ostrimi-n_ru_1586717247.pdf (In Russ.)

32. Jin H., Hong C., Chen S. et al. Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. Stroke & Vascular Neurology 2020;0. DOI: 10.1136/svn-2020-000382.

33. Bikdeli B., Madhavan M.V., Jimenez D. et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020;Apr 15:published online. DOI: 10.1016/j.jacc.2020.04.031. PMID: 32311448.

34. French J.A., Brodie M.J., Caraballo R. et al. Keeping people with epilepsy safe during the Covid-19 pandemic. Neurology 2020;Apr 23:published online. DOI: 10.1212/WNL.0000000000009632. PMID: 32327490.

35. Russo E., Iannone L. Clinically relevant drug-drug interaction between AEDs and medications used in the treatment of COVID-19 patients (26.03.2020). URL: https://www.ilae.org/files/dmfile/Antiepileptic-drugs-interactions_in_COVID-19.pdf.

36. Chen H.Y., Albertson T.E., Olson K.R. Treatment of drug-induced seizures. Br J Clin Pharmacol 2016;81(3):412–9. DOI: 10.1111/bcp.12720. PMID: 26174744.

37. Plaquenil-hydroxychloroquine sulfate. Summary of Product Characteristics 2020;Mar 2020. URL: https://www.medicines.org.uk/emc/product/1764/smpc.

38. Krzeminski P., Lesiak A., Narbutt J. Seizures as a rare adverse effect of chloroquine therapy in systemic lupus erythematosus patients: a case report and literature survey. Postepy Dermatol Alergol 2018;35(4):429–30. DOI: 10.5114/ada.2018.77675. PMID: 30206460.

39. Lai S.L., Hsu M.T., Chen S.S. The impact of SARS on epilepsy: the experience of drug withdrawal in epileptic patients. Seizure 2005;14:557–61. DOI: 10.1016/j.seizure.2005.08.010. PMID:16188463.

40. ABN Service Committee working group 2019-20 Guidance on neurology referral management. URL: https://cdn.ymaws.com/www.theabn.org/resource/collection/65C334C7-30FA-45DB-93AA-74B3A3A20293/29.03.20_ABN_Guidance_on_Referral_Management.pdf.

41. Chow N., Fleming-Dutra K., Gierke R. et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep 2020;69(13):382–6. DOI: 10.15585/mmwr.mm6913e2. PMID: 32240123. URL: https://www.centrems.com/downloads/MAVRSCOVID-19.pdf.

42. Wang T., Du Z., Zhu F. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet 2020;395(10228):e52. DOI: 10.1016/S0140-6736(20)30558-4. PMID: 32171074.

43. Wang H., Li T., Barbarino P. et al. Dementia care during COVID-19. Lancet 2020;395(10231):1190–1. DOI: 10.1016/S0140-6736(20)30755-8. PMID: 32240625.

44. Papa S.M., Brundin P., Fung V.S.C. et al. Impact of the COVID-19 pandemic on Parkinson’s disease and movement disorders. Movement Disorders 2020;Apr 6:published online. DOI: 10.1002/mds.28067. PMID: 32250460.

45. Waldman G., Mayeux R., Claassen J. Preparing a neurology department for SARS-CoV-2 (COVID-19). Early experiences at Columbia university Irving medical center and the New York Presbyterian hospital in New York city. Neurology 2020;94:1–6. DOI:10.1212/WNL.0000000000009519. PMID:32253352.

46. Stoessl A.J., Bhatia K.P., Merello M. Movement disorders in the world of COVID‐19. Movement Disorders 2020;Apr 6:published online. DOI: 10.1002/mds.28069. PMID: 32250468.

47. Fanciulli A., Habek M., Carneiro D. et al. COVID-19: statement by the Autonomic nervous system disorders Scientific Panel(07.04.2020). URL: https://www.eanpages.org/2020/04/17/covid-19-statement-by-the-autonomic-nervoussystem-disorders-scientific-panel.

48. Covid-19 and people with neuromuscular disorders: World Muscle Society position and advice. Version 1(28.03.2020). URL: https://www.worldmusclesociety.org/files/COVID19/WMS%20Covid-19%20advice%2028-03-2020%201800.pdf.

49. Sharrack N. British Cardiovascular Society. COVID-19: implications for cardiologists (07.04.2020). URL: https://www.britishcardiovascularsociety.org/resources/editorials/articles/covid-19-implications-cardiologists.

50. Mao L., Jin H., Wang M. et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurology 2020;Apr 10:published online. DOI: 10.1001/jamaneurol.2020.1127. PMID:32275288.